ML
HEPA

McAdam LLC’s Hepion Pharmaceuticals HEPA Stock Holding History

McAdam LLC’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-62
Closed -$48.3K – 266
2023
Q1 		$48.3K Hold
62
– – ﹤0.01% 245
2022
Q4 		$71K Hold
62
– – 0.01% 187
2022
Q3 		$31K Hold
62
– – ﹤0.01% 212
2022
Q2 		$36K Hold
62
– – ﹤0.01% 215
2022
Q1 		$80K Hold
62
– – 0.01% 206
2021
Q4 		$71K Buy
62
+6
+11% +$8.22K 0.01% 187
2021
Q3 		$86K Hold
56
– – 0.01% 175
2021
Q2 		$86K Buy
56
+19
+51% +$34.8K 0.01% 172
2021
Q1 		$67K Buy
+37
New +$81.1K 0.01% 158

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

McAdam LLC's HEPA Position: Q2 2023 in Review

McAdam LLC sold out of Hepion Pharmaceuticals (HEPA) in Q2 2023, closing a stake of 62 shares — an estimated $48.3K sold.

McAdam LLC first reported a position in HEPA in Q1 2021 and held it in 9 quarters. The position peaked at $86K in Q3 2021. 16 funds tracked by Wall St. Rank hold HEPA as of Q2 2023.

  • McAdam LLC reported no remaining Hepion Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • McAdam LLC sold 62 Hepion Pharmaceuticals shares in Q2 2023, an estimated $48.3K.
  • McAdam LLC first reported a position in Hepion Pharmaceuticals in Q1 2021 and held it in 9 quarters.
  • McAdam LLC's Hepion Pharmaceuticals position peaked at $86K in Q3 2021.
  • 16 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2023.

Based on McAdam LLC's 13F filing for Q2 2023, filed 2 Aug 2023.